Radiodermatitis - Pipeline Insight, 2021

This “Radiodermatitis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Radiodermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Radiodermatitis Understanding

Radiodermatitis: Overview

Radiodermatitis (radiation dermatitis, radiation-induced skin reactions, or radiation injury) is a significant side effect of ionizing radiation delivered to the skin during cancer treatment as well as a result of nuclear attacks and disasters. More specifically, 95 % of cancer patients receiving radiation therapy will develop some form of radiodermatitis, including erythema, dry desquamation, and moist desquamation. These radiation skin reactions result in a myriad of complications, including delays in treatment, diminished aesthetic appeal, and reduced quality of life. Radiation-induced dermatitis can be classified as acute or chronic. Acute radiation dermatitis occurs within 90 days of exposure to radiation. The patient may have skin changes ranging from faint erythema (reddening) and desquamation (peeling skin) to skin necrosis (death of skin cells) and ulceration, depending on the severity of the reaction. The onset of chronic radiation dermatitis may occur from 15 days to 10 years or more after the beginning of radiation therapy. It is an extension of the acute process and involves further inflammatory changes in the skin. Topical corticosteroids may be prescribed for radiation dermatitis for 2 to 4 weeks. Many small studies have investigated the use of topical therapies, as either preventative agents or for management of skin reactions as they occur.

"Radiodermatitis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Radiodermatitis pipeline landscape is provided which includes the disease overview and Radiodermatitis treatment guidelines. The assessment part of the report embraces, in depth Radiodermatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Radiodermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Radiodermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Radiodermatitis.

Radiodermatitis Emerging Drugs Chapters

This segment of the Radiodermatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Radiodermatitis Emerging Drugs

Tempol: Adamis Pharmaceuticals

The MTS-01 (Tempol) drug product is a topical gel containing 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl. The composition of MTS-01 is used for indications requiring topical applications of the lead compound. Such indications include the prevention of radiation dermatitis, psoriasis, and other inflammatory skin conditions. MTS-01 blocks inflammatory pathways. TEMPOL is a stable free radical that readily reacts with toxic oxygen species including superoxide (O2.-), hydroxyl radical (.OH), and secondary radicals produced by the oxidation of biological macromolecules, including lipid radicals. TEMPOL reaches every cell in the body and repairs damaged cellular environments thereby increasing mitochondria output and improving overall cellular function. Adamis has a worldwide license to use Tempol for the use of reducing radiation dermatitis in patients undergoing treatment for cancer. The drug is currently being evaluated in Phase III stage of development for the treatment of Radiodermatitis.

Radiodermatitis: Therapeutic Assessment

This segment of the report provides insights about the different Radiodermatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Radiodermatitis

There are approx. 5+ key companies which are developing the therapies for Radiodermatitis. The companies which have their Radiodermatitis drug candidates in the most advanced stage, i.e. Phase III include, Adamis Pharmaceuticals.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Radiodermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Radiodermatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Radiodermatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Radiodermatitis drugs.

Radiodermatitis Report Insights

• Radiodermatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Radiodermatitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Radiodermatitis drugs?
• How many Radiodermatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Radiodermatitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Radiodermatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Radiodermatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.